FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Company

Rigel Pharmaceuticals

Pharmaceutical intelligence for Rigel Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalAugust 20, 2026

Phase 2 Study of Olutasidenib with Hypomethylating Agents in IDH1-mutated Hematologic Malignancies

A Phase 2 study is evaluating the efficacy and safety of olutasidenib in combination with hypomethylating agents in patients with IDH1-mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.